Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

Sabrina Sacconi, EAN 2023: The MycarinG study – rozanolixizumab in the treatment of muscle-specific kinase autoantibody-positive myasthenia gravis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 10th 2023

Muscle-specific kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) is usually more clinically severe than acetylcholine receptor autoantibody-positive (AChR-Ab+) gMG. The Phase 3 MycarinG study analysed rozanolixizumab in patients with AChR-Ab+ or MuSKAb+ gMG. Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes the take-home messages from her presentation of the results of the study.

The abstract ‘EPO-391 Rozanolixizumab in muscle-specific kinase autoantibody-positive myasthenia gravis: Further analyses from MycarinG study’ was presented at the annual European Academy of Neurology (EAN), July 1–4, 2023

Questions

  1. What are the current treatment options for muscle-specific kinase autoantibody-positive myasthenia gravis? (00:14)
  2. What were the aims and rationale of the MycarinG study? (00:46)
  3. What was the study design and methodology? (01:10)
  4. Please can you summarize the key findings from the study? (01:45)
  5. What conclusions can be made, and how might this impact future clinical practice? (02:25)

Disclosures: Sabrina Sacconi is a consultant for Dyne therapeutics and Sanofi. She has received grant/research support from Roche, Biogen and Lupin, and is a member of the advisory board for UCB pharma, Sanofi, Fulcrum, Alexion and Roche.

Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson.

Filmed as highlight of EAN 2023.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup